Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Arno Verleye; Veerle Wijtvliet; Steven Abrams; Rachel Hellemans; Rania Bougrea; Annick Massart; Lissa Pipeleers; Karl Martin Wissing; Kevin K Ariën; Benedicte Y De Winter; Pierre Van Damme; Daniel Abramowicz; Kristien J Ledeganck

doi:10.1093/ndt/gfac174

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Arno Verleye, Veerle Wijtvliet, Steven Abrams, Rachel Hellemans, Rania Bougrea, Annick Massart, Lissa Pipeleers, Karl Martin Wissing, Kevin K Ariën, Benedicte Y De Winter, Pierre Van Damme, Daniel Abramowicz, Kristien J Ledeganck

Virology

Research output: Contribution to journal › A1: Web of Science-article › peer-review

16 Downloads (Pure)

Abstract

BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.

METHODS: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.

RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).

CONCLUSIONS: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.

Original language	English
Journal	Nephrology, Dialysis, Transplantation
Volume	37
Issue number	8
Pages (from-to)	1566-1575
Number of pages	10
ISSN	0931-0509
DOIs	https://doi.org/10.1093/ndt/gfac174
Publication status	Published - 2022

Keywords

2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
BNT162 Vaccine
COVID-19/prevention & control
Humans
Organ Transplantation
RNA, Messenger
Seroconversion
Transplant Recipients
Vaccination
Vaccines

Access to Document

10.1093/ndt/gfac174Licence: Unspecified

2022ndtr1566Final published version, 776 KBLicence: Unspecified

Cite this

Verleye, A., Wijtvliet, V., Abrams, S., Hellemans, R., Bougrea, R., Massart, A., Pipeleers, L., Wissing, K. M., Ariën, K. K., De Winter, B. Y., Van Damme, P., Abramowicz, D., & Ledeganck, K. J. (2022). Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. Nephrology, Dialysis, Transplantation, 37(8), 1566-1575. https://doi.org/10.1093/ndt/gfac174

@article{a7c614ffaa4f44ac81fd47d31fbf84f9,

title = "Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis",

abstract = "BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.METHODS: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).CONCLUSIONS: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.",

keywords = "2019-nCoV Vaccine mRNA-1273, Antibodies, Viral, BNT162 Vaccine, COVID-19/prevention & control, Humans, Organ Transplantation, RNA, Messenger, Seroconversion, Transplant Recipients, Vaccination, Vaccines",

author = "Arno Verleye and Veerle Wijtvliet and Steven Abrams and Rachel Hellemans and Rania Bougrea and Annick Massart and Lissa Pipeleers and Wissing, {Karl Martin} and Ari{\"e}n, {Kevin K} and {De Winter}, {Benedicte Y} and {Van Damme}, Pierre and Daniel Abramowicz and Ledeganck, {Kristien J}",

note = "FTX; {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.",

year = "2022",

doi = "10.1093/ndt/gfac174",

language = "English",

volume = "37",

pages = "1566--1575",

journal = "Nephrology, Dialysis, Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "8",

}

Verleye, A, Wijtvliet, V, Abrams, S, Hellemans, R, Bougrea, R, Massart, A, Pipeleers, L, Wissing, KM, Ariën, KK, De Winter, BY, Van Damme, P, Abramowicz, D & Ledeganck, KJ 2022, 'Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis', Nephrology, Dialysis, Transplantation, vol. 37, no. 8, pp. 1566-1575. https://doi.org/10.1093/ndt/gfac174

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. / Verleye, Arno; Wijtvliet, Veerle; Abrams, Steven et al.
In: Nephrology, Dialysis, Transplantation, Vol. 37, No. 8, 2022, p. 1566-1575.

Research output: Contribution to journal › A1: Web of Science-article › peer-review

TY - JOUR

T1 - Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

AU - Verleye, Arno

AU - Wijtvliet, Veerle

AU - Abrams, Steven

AU - Hellemans, Rachel

AU - Bougrea, Rania

AU - Massart, Annick

AU - Pipeleers, Lissa

AU - Wissing, Karl Martin

AU - Ariën, Kevin K

AU - De Winter, Benedicte Y

AU - Van Damme, Pierre

AU - Abramowicz, Daniel

AU - Ledeganck, Kristien J

N1 - FTX; © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.

PY - 2022

Y1 - 2022

N2 - BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.METHODS: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).CONCLUSIONS: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.

AB - BACKGROUND: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.METHODS: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.RESULTS: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).CONCLUSIONS: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.

KW - 2019-nCoV Vaccine mRNA-1273

KW - Antibodies, Viral

KW - BNT162 Vaccine

KW - COVID-19/prevention & control

KW - Humans

KW - Organ Transplantation

KW - RNA, Messenger

KW - Seroconversion

KW - Transplant Recipients

KW - Vaccination

KW - Vaccines

U2 - 10.1093/ndt/gfac174

DO - 10.1093/ndt/gfac174

M3 - A1: Web of Science-article

C2 - 35544087

SN - 0931-0509

VL - 37

SP - 1566

EP - 1575

JO - Nephrology, Dialysis, Transplantation

JF - Nephrology, Dialysis, Transplantation

IS - 8

ER -

Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis

Abstract

Keywords

Access to Document

Fingerprint

Cite this